Clinical Trials Logo

Clinical Trial Summary

This clinical study will test the effects of a drug called apremilast in oligoarticular psoriatic arthritis with less than 5 years of disease duration. In previous studies, apremilast has been shown to be safe and efficacious in reducing signs and symptoms of psoriatic arthritis, as well as improving physical function. This study will compare the effects of apremilast to placebo on psoriatic arthritis subjects in which the number of affected joints is limited (greater than 1 but less or equal to 4). About 285 patients worldwide will take part in this study.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03747939
Study type Interventional
Source Amgen
Contact
Status Completed
Phase Phase 4
Start date December 31, 2018
Completion date July 5, 2023

See also
  Status Clinical Trial Phase
Completed NCT02181673 - A Study of Golimumab in Participants With Active Psoriatic Arthritis Phase 3
Recruiting NCT04936308 - Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent Phase 3
Terminated NCT00090129 - Onercept in the Treatment and Re-Treatment of Subjects With Moderate to Severe Plaque Psoriasis Phase 3
Withdrawn NCT03625089 - Impact of Nurse-led Programme With Carotid Ultrasound on Addressing Cardiovascular Risk in Patients With Arthritis N/A
Recruiting NCT05571696 - Mind Matters: A High Touch, Low Cost Approach to Improving Mental Health Outcomes in Patients With Psoriatic Diseases N/A
Active, not recruiting NCT05071664 - A Study of Guselkumab and Golimumab Combination Therapy in Participants With Active Psoriatic Arthritis Phase 2
Completed NCT00938015 - Study Evaluating Safety and Adherence to Treatment With Etanercept in Adults With Psoriatic Arthritis N/A
Suspended NCT03703934 - Central Pain Mechanisms in Patients With Hand-Osteoarthritis, Psoriatic Arthritis and Healthy Controls
Recruiting NCT05092269 - A Long-term Extension Study of Ustekinumab in Pediatric Participants Phase 3
Terminated NCT05083078 - A Study of Guselkumab and Risankizumab in Healthy Participants and Participants With Psoriatic Arthritis Phase 1
Completed NCT02436785 - Do Inflammatory Arthritis Inpatients Receiving Group Music Therapy Improve Pain Compared to Music Listening? N/A
Completed NCT02294227 - 16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Psoriatic Arthritis Phase 3
Completed NCT00998829 - Study Evaluating The Prevalence Of Undiagnosed Psoriatic Arthritis In Patients With Plaque Psoriasis N/A
Completed NCT00760669 - An Observational Study of Infliximab Injection in Ankylosing Spondylitis, Rheumatoid Arthritis, Psoriatic Arthritis and Psoriasis Participants Phase 4
Completed NCT00367237 - Remicade Study in Psoriatic Arthritis Patients Of Methotrexate-Naïve Disease (RESPOND) (Study P04422) Phase 3
Completed NCT00051623 - A Study of the Safety and Effectiveness of Infliximab for the Treatment of Psoriatic Arthritis Phase 3
Withdrawn NCT04680676 - A Study to Test Different Doses of BI 730357 and Find Out Whether They Reduce Symptoms in People With Active Psoriatic Arthritis Phase 2
Completed NCT03008590 - Low Dose Naltrexone for Chronic Pain From Arthritis Phase 2
Recruiting NCT05657847 - Novel Complex Radiodiagnostics of Peripherial Arthropathies
Completed NCT02875184 - A Study of Apremilast Use and Effectiveness in Patients With Psoriatic Arthritis in The Netherlands